Vandel S, Bertschy G, Bonin B, Nezelof S, François T H, Vandel B, Sechter D, Bizouard P
Laboratoire de Pharmacologie Clinique et Besançon, France.
Neuropsychobiology. 1992;25(4):202-7. doi: 10.1159/000118838.
After a review of a pharmacokinetic interaction between tricyclic antidepressants (TCA) and fluoxetine the authors report their own data. They confirm the existence of an interaction of TCA with fluoxetine, in clinical practice, but the fluoxetine was not associated in all cases with a marked increase of TCA plasma levels. The increase appeared especially high with clomipramine (n = 4) and imipramine (n = 3), and lower or dose-dependent with amitriptyline (n = 4). The pharmacokinetic change did not induce side effects in the patients, even when the total TCA plasma level increased to 965 (clomipramine) or 785 (imipramine) ng/ml. The authors then discuss the clinical implication and the possible mechanism of action.
在回顾了三环类抗抑郁药（TCA）与氟西汀之间的药代动力学相互作用后，作者报告了他们自己的数据。他们证实在临床实践中TCA与氟西汀存在相互作用，但并非在所有情况下氟西汀都会导致TCA血浆水平显著升高。氯米帕明（n = 4）和丙咪嗪（n = 3）的升高尤为明显，而阿米替林（n = 4）的升高较低或呈剂量依赖性。即使TCA血浆总水平升至965（氯米帕明）或785（丙咪嗪）ng/ml，药代动力学变化也未在患者中引发副作用。作者随后讨论了临床意义及可能的作用机制。
